# A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

> **NCT06776952** · PHASE3 · RECRUITING · sponsor: **Evopoint Biosciences Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Relapsed/Refractory Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** XNW5004 ; Chidamide placebo
- **DRUG:** XNW5004 placebo; Chidamide

## Key facts

- **NCT ID:** NCT06776952
- **Lead sponsor:** Evopoint Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-10
- **Primary completion:** 2028-01
- **Final completion:** 2028-04
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06776952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06776952, "A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06776952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*